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The Zinc Ionophore PCI-5002 Radiosensitizes Non-small
Cell Lung Cancer Cells by Enhancing Autophagic Cell
Death
Kwang Woon Kim, PhD, Christina K. Speirs, PhD, Dae Kwang Jung, BS, and Bo Lu, MD, PhD
Introduction: A major focus of cancer research is to identify
compounds that sensitize resistant cancer cells to radiation treat-
ment. Lung cancer cells, in particular, have high rates of radioresis-
tance that lead to treatment failure. We have previously shown that
the autophagy induced in the context of decreased apoptosis confers
radiosensitivity to prostate and lung cancer cells. Zinc supplemen-
tation has antiapoptotic effects in cell culture. In addition, the
accumulation of zinc in response to oxidative stress has been
associated with increased autophagy in astrocyte and breast cancer
cells.
Methods: In this study, we hypothesized that the zinc ionophore
PCI-5002 radiosensitizes lung cancer cells by inducing autophagic
cell death. To test this hypothesis, we used a combination of in vitro
and in vivo approaches, including clonogenic assays to test for
radiosensitivity, biochemical analyses of apoptosis and autophagy,
and a xenograft mouse model of tumor growth.
Results: We found that PCI-5002 reduced clonogenic survival in
treated cells compared with untreated cells (0.03% versus 0.1%
surviving fraction, p  0.001). The increased radiosensitive fraction
of PCI-5002-treated cells was accompanied by increased autophagy.
PCI-5002 treatment also reduced caspase-3 cleavage. In an irradi-
ated xenograft mouse model, the tumor growth of irradiated, PCI-
5002-treated mice was slower than untreated, irradiated mice (25
days versus 22 days to reach a 1.0 cm3 tumor size).
Conclusions: PCI-5002 treatment sensitizes lung cancer cells to
radiation, both in vitro and in vivo. This data suggest that PCI-5002
could potentially treat radioresistant/locally advanced lung cancer
by amplifying the effects of radiotherapy.
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Lung cancer is the most deadly cancer for men and womenworldwide. It is projected that in 2010, more than 200,000
new cases of lung cancer will be diagnosed within the United
States alone and that 120,000 Americans will die of lung
cancer.1 Although chemoradiation therapy has increased
treatment efficacy, relapsed disease in lung cancer remains
high due to tumor resistance.2,3 Therefore, finding agents that
maximize the tumoricidal effects of chemotherapy or radia-
tion treatment while minimizing the toxicity to adjacent
normal cells is of great importance to the treatment of lung
cancer.4,5
Death of the irradiated cell can occur through cell cycle
arrest, DNA repair pathway activation, or the activation of
cell death pathways such as apoptosis and autophagy. Apo-
ptosis is activated by either intrinsic or extrinsic stimulation
and leads to the activation of caspase enzymes, which results
in cellular changes such as mitochondria permeabilization
and DNA fragmentation. Activation of antiapoptotic genes
(Bcl-2 and Bcl-xL) or inhibition of proapoptotic genes (Bax
and Bak) is correlated with cancer progression and increased
resistance to therapy in multiple cancer types. Lung cancer, in
particular, is associated with defects in the intrinsic pathway.
For example, non-small cell lung cancer (NSCLC) cells were
found to express caspase-9S, a truncated procaspase that
inhibited the proapoptotic protein apoptotic protease activat-
ing factor 1.6 Therefore, increasing apoptosis with cancer
therapy is a goal of drug development that has led to proapo-
ptotic drugs such as oblimersen (Bcl-2 antisense oligonucle-
otide) and Gossypol (inhibitor of Bcl-2, Bcl-xL, and MCL1).
Nevertheless, oblimersen showed no significant benefit when
combined with carboplatin and etoposide in patients with
advanced NSCLC.7 The treatment of patients with NSCLC
with mapatumumab, a TRAIL receptor activator, also did
not result in significant improvement in disease, as put
forth by the RECIST criteria.8 These data suggest that
therapeutically increasing apoptosis is insufficient to halt
lung cancer progression.
In contrast to apoptosis, autophagy has been ascribed
roles in both survival and cell death.9,10 Autophagy, or pro-
grammed cell death type II, is the process by which the cell
engulfs its own organelles through the creation of autopha-
gosomes. During autophagy, double-membrane autophago-
some vesicles form and then fuse with lysosomes to generate
autophagolysosomes. The contents of the autophagolyso-
somes are subsequently degraded. Autophagy is reduced by
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the induction of oncogenic signaling pathways such as the
PI3K/Akt/mTOR pathway and increased with rapamycin an-
alogs or Bcl-2 inhibitors, suggesting that it is an important
factor in the progression of cancer.11–14 In addition, Beclin-1,
a protein required for autophagy, is a tumor suppressor, as are
the other components of the Beclin-1 complex (UVRAG,
Bif-1, Ambra).15,16 This process can be prodeath or prosur-
vival, depending on the cellular context.17–20 In yeast, au-
tophagy is a survival mechanism that creates additional en-
ergy sources from the cellular contents. Prior work, however,
shows that the activation of Beclin-1 was associated with
increased cell death.21 There are multiple models of how
autophagy could cause death: by activating apoptosis, reduc-
ing cell viability with overexuberant cellular digestion, or by
selectively degrading prosurvival factors in the cell.10
The role of autophagy during cancer progression is not
well understood. Most studies suggest that autophagy acts to
oppose tumor progression. First, early studies in rat hepato-
cytes showed that cancer cells have less autophagy than their
normal counterparts.22,23 Second, there are data showing that
increased mTOR signaling, which occurs in many cancer
types, is associated with decreased autophagy. Third, Be-
clin-1 was found to be monoallelically deleted in breast
carcinomas, suggesting that defects in autophagy act through
a haploinsufficient mechanism. Indeed, mammary epithelial
cells with an allelic loss of Beclin-1 were sensitized to
metabolic stress and exhibited more tumor progression than
cells that had intact autophagy.24 Defects in autophagy are
thought to increase tumor progression because of the accu-
mulation of reactive oxygen species (ROS) and uncorrected
DNA damage.16,25 Although these data propose that au-
tophagy acts as a tumor suppressing mechanism, other data
suggest that the role of autophagy is dependent on the stage
of cancer, because advanced cancer cells exhibited increased
levels of autophagy. Furthermore, Jin and White26 suggest
that by recycling cellular proteins and organelles in times of
metabolic stress, autophagy may serve to minimize ineffec-
tive cellular products (protein and organelle quality control)
and to maintain ATP levels in times of metabolic stress
(metabolic stress management hypothesis). In this context,
cancer cells probably use autophagy as a prosurvival mech-
anism to cope with decreased nutrient supply or increased
metabolic demands.27 These studies suggest that the thera-
peutic effect of activating autophagy in cancer cells is influ-
enced by the disease stage and the microenvironment. Inter-
estingly, inhibiting apoptotic cell death with zVAD, a caspase
inhibitor, resulted in increased autophagic cell death that was
dependent on ATG7 and Beclin-1.20 Therefore, the role of
autophagy in cancer cell survival is an especially pertinent
question with the increased use of proapoptotic agents in
chemotherapy: what are the cellular outcomes?
We have shown that in cells with decreased apoptosis
(Bax/Bak-/- mouse embryonic fibroblasts [MEFs]) increased
autophagy was associated with the radiosensitization of cells
compared with wild-type (WT) MEFs.12 Inhibiting mTOR
signaling with Everolimus (Rad001) enhanced both au-
tophagy and radiosensitization in PTEN-null prostate cells
when apoptosis was decreased (by Bax/Bak antisense oligo-
nucleotides or caspase inhibition).28 Increased autophagy and
radiosensitivity were present in caspase-3/7-/- MEFs, an effect
that was modulated with ATG5 and Beclin-1 siRNAs and
enhanced with ATG5 and Beclin-1 overexpression.29 We
have also previously demonstrated that these findings also
occur in vivo, using a NSCLC tumor xenograft model of
H460 cells implanted into nude athymic mice.29 Inhibiting
apoptosis with M867, a caspase-3 inhibitor, resulted in de-
creased tumor volume in treated mice.29 In addition, the
xenograft mice had decreased vasculogenesis in the irradiated
tumors with M867 treatment. Studies from other laboratories
have also identified radiosensitization in breast cancer and
glioma tumors when autophagy is induced.30,31 These results
suggested that activation of autophagy in cancer cells, in the
context of reduced apoptosis, holds therapeutic promise.
Zinc first attracted our attention as a potential therapeu-
tic candidate because of its ascribed role in regulating apo-
ptosis. Zinc is an essential element for cell function—it is
involved in enzymatic reactions, gene expression, DNA syn-
thesis, regeneration, immunity, neurotransmission, and pho-
toreceptor function.32 Zinc toxicity, although rare, can be a
medical emergency because of neurologic lethargy, respira-
tory distress, gastrointestinal dysfunction, lymphocyte defi-
cits, and copper deficiency.33 In particular, long-term use can
lead to interference with copper uptake. Cell culture studies
have also shown that zinc could reduce apoptosis through
several mechanisms—by inhibiting DNA fragmentation
through interference with a Ca-/Mg-dependent endonuclease
or by inhibiting caspase-3 or Bak function.34–36 Interestingly,
increasing intracellular zinc concentrations in laryngeal cells
led to increased apoptotic cell death (150 M) and necrotic
cell death (300–750 M).32,37 The involvement of zinc in
autophagy has been demonstrated in mouse astrocyte culture.
In this study, induced oxidative stress (by H2O2 or FeCl2
treatment) resulted in the accumulation of endogenous zinc in
autophagosomes. This led to increased cell death that could
be reversed with autophagy inhibitor treatment.38 Another
study showed that MCF-7 breast cancer cells treated with
Tamoxifen had higher levels of autophagy and endogenous
zinc accumulation in autophagosomes than untreated cells.39
Treatment with an antioxidant (N-acetyl-L-cysteine) blunted
zinc accumulation and autophagic cell death. These results
suggest that zinc treatment can enhance autophagic cell death
by increasing the toxicity of oxidative stress. Nevertheless,
whether zinc can sensitize cells to the stress of radiation
therapy was unknown.
PCI-5002, a zinc ionophore, has been shown to de-
crease cell proliferation in treated A549 lung cancer cells and
PC3 prostate cancer cells.40 Therefore, we hypothesized that
PCI-5002 treatment might radiosensitize treated cells by the
induction of autophagy at the expense of apoptosis. In this
study, we show that PCI-5002 treatment does indeed increase
autophagy in H460 lung cancer cells. This finding is associ-
ated with increased radiosensitization and decreased caspase
cleavage in PCI-5002-treated cells. These effects were abol-
ished in bax/bak-/- MEF cells, suggesting that the action of
PCI-5002 is dependent on Bax/Bak function. We also de-
scribe the effects of PCI-5002 treatment on tumor volume and
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tumor cell proliferation in an in vivo irradiated xenograft
mouse model. This data represent the first in vivo demonstra-
tion of the effects of zinc on cancer cell death. PCI-5002
treatment may provide the beneficial effects of zinc on cancer
cell death while subverting the toxicity of free zinc adminis-
tration. Therefore, we propose that PCI-5002 is a promising
radiosensitizing agent that may be effective in magnifying the
outcomes of radiation treatment for lung cancer.
MATERIALS AND METHODS
Cell Culture
Primary MEFs were derived from WT and Bax/Bak
double knockout (DKO) mice and immortalized by transfec-
tion with a plasmid containing SV40-T-antigen (provided by
Dr. Stanley J. Korsmeyer, Dana-Farber Cancer Institute,
Boston, MA). MEFs were cultured in DMEM (Invitrogen
Corporation) supplemented with 10% fetal bovine serum, 1%
penicillin-streptomycin, and 0.5 mmol/L 2-mercaptoethanol.
H460 lung cancer cells were cultured in RPMI 1640 (Invit-
rogen, Grand Island, NY) supplemented with 10% fetal
bovine serum and 1% penicillin-streptomycin at 37°C and
humidified 5% CO2. PCI-5002 was obtained from Pharma-
cyclics, Inc.
Clonogenic Assay
MEFs cells and Bax/Bak DKO MEFs cells were treated
with 5% mannitol or PCI-5002 (300 nM). H460 lung cancer
cells were treated with 5% mannitol or PCI-5002. After 2
hours, they were then irradiated with 0 to 6 Gy as indicated
at a dose rate of 1.8 Gy/min, by using a 137 Cs irradiator for
48 hours (J.L. Shepherd and Associates, Glendale, CA) and
then washed with phosphate-buffered saline (PBS) for two
times. After washing, cells were incubated at 37°C for 8 to 10
days. Cells were fixed for 15 minutes with 3:1 methanol:
acetic acid and stained for 15 minutes with 0.5% crystal
violet (Sigma) in methanol. After staining, colonies were
counted using a cutoff of 50 viable cells. Surviving fraction
was calculated as (mean colony counts)/(cells inoculated)
(plating efficiency), where plating efficiency was defined as
(mean colony counts)/(cells inoculated for nonirradiated con-
trols). DER was calculated as the dose (Gy) for radiation
alone divided by the dose (Gy) for radiation plus PCI-5002
(normalized for PCI-5002 toxicity) necessary for a surviving
fraction of 0.25. Experiments were conducted in triplicate and
mean, SD, and p values were calculated.
Immunoblotting
Cells (0.5  106) were treated with various Gy doses
and drugs. They were collected at various time points and
then were washed with ice-cold PBS twice before the addi-
tion of lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl,
20 mM ethylenediaminetetraacetic acid, 1% NP40, 50 mM
NaF, 1 mM Na3VO4, 1 mM NaMO4, and cocktail inhibitor)
(Sigma, 5 l/ml). Protein concentration was quantified by the
Bio-Rad method. Equal amounts of protein were loaded into
each well and separated by 12.5% sodium dodecyl sulfate-
PAGE gel, followed by transfer onto PVDF membranes
(BIO-RAD). Membranes were blocked by use 5% nonfat dry
milk in PBS-T for 1 hour at room temperature. The blots were
then incubated with caspase-3 (Cell signaling), cytochrome c
(BD Biosciences), and actin antibodies for 1 hour at 4°C.
Goat antirabbit IgG secondary (1:5000, Santa Cruse Biotechnol-
ogies) was incubated for 45 minutes at room temperature.
Immunoblots were developed by using the chemiluminescence
detection system (PerkinElmer) according to the manufacturer’s
protocol and autoradiography.
In Vitro Cytochrome c Release
Mitochondria isolation was performed as described
previously in Bak KO and Bax KO MEF cells (Tudor
Moldoveanu, 2006). For the cytochrome c release assay, 50
l of the reaction was prepared with 25 l of mitochondria,
3 l of PCI-5002 (300 nM or 1 M), and 2.5 l Bid and of
19.5 l of MIB buffer (200 mM mannitol, 70 mM sucrose, 10
mM HEPES, and 1 mM EGTA) and then was incubated at
37°C for 3 hours.
Mitochondria were spun down from the reaction at
9000 rpm for 5 minutes at 4°C. The supernatants were
analyzed for cytochrome c by Western blotting.
Measurement of Apoptosis
Cells (5  105) were plated into 10 mm dishes for each
data point. After 24 hours of 37°C incubation, H460 cells
were treated with PCI-5002 (0.3 M and 7.5 M for 2 hours)
and immediately irradiated with 10 Gy. After 48 hours, cells
were treated with 1.5 ml of Accutase (Innovative cell Tech-
nologies, Inc, San Diego, CA) for 4 minutes and then counted
for each sample. Cells were centrifuged and resuspended in
1X binding buffer at a concentration of 1  106 cells/ml.
Cells (1  105 cells/100 l) were transferred in a 5 ml FACS
tube with 1.2 l of Annexin V FITC and 1.2 l of PI. After
incubation for 15 minutes at RT in the dark, 300 l of 1X
binding buffer was added to each tube. The rate of apoptosis
was measured using the Annexin V-fluorescein isothiocya-
nate apoptosis detection kit I (BD Pharmingen, San Diego,
CA) with flow cytometry.
Autophagy Assay
MEFs cells and H460 cells were transfected with 2.5
mg of GFP-LC3 expression plasmid (gift from Dr. Norboru
Mizushima)19 using the lipofectamine reagent (Invitrogen
Life Technologies). After 24 hours, cells were treated with 5
Gy of radiation, with or without PCI-5002. After 48 hours,
the fluorescence of GFP-LC3 was observed using confocal
fluoroscopy.
Tumor Volume Assessment
Human H460 lung cancer cells were used in a xenograft
model in female athymic nude mice (nu/nu) (5 to 6 weeks old
[Harlan Sprague Dawley Inc., Indianapolis, IN]). A suspen-
sion of 1  106 cells in 50 ml volume was injected subcu-
taneously into the left posterior flank of mice using a 27K-
gauge needle. Tumors were grown for 6 to 8 days until
average tumor volume reached 0.1 cm3 treatment groups
consisted of vehicle control (in 5% mannitol), PCI-5002 (100
nmol/kg), vehicle plus radiation, and PCI-5002 plus radia-
tion. Each treatment group contained five mice. Mannitol
(5%) or PCI-5002 was given daily by intraperitoneal injection
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at doses of 100 nmol/kg for 7 days. In the case of combina-
tion treatment, drug or vehicle was given for 2 days before
the first dose of irradiation. Mice in radiation groups were
irradiated 1 hour after drug or vehicle treatment with daily 2
Gy fractions given over 5 days. Tumors on the flanks of the
mice were irradiated using an x-ray irradiator (Therapax,
Agfa NDT, Inc., Lewis Town, PA). The nontumor bearing
parts of the mice were shielded by lead blocks. Tumors were
measured 2 to 3 times weekly in three perpendicular dimen-
sions using a Vernier caliper, and volume was calculated
using the modified ellipse volume formula (volume 
[height  width  depth]/2). Growth delay was calculated
for treatment groups relative to control tumors.
Histological Sections, Ki67, and Active
Caspase-3 Staining
Mice were implanted with H460 cells and treated as
described earlier (PCI-5002: 100nmol/kg) in the tumor vol-
ume studies. After 7 days of daily treatments, mice were
killed, and tumors were paraffin fixed. Ki67 and active
caspase-3 staining were performed in the Vanderbilt Univer-
sity pathology core laboratory using standard protocols. This
was done in triplicate, and the average of the three counts was
calculated.
RESULTS
PCI-5002 Inhibits Apoptosis and Increases
Radiosensitivity in H460 NSCLC Cells
Because PCI-5002 treatment has been shown to reduce
cell proliferation in A549 lung cancer cells,40 we were inter-
ested in whether treating H460 lung cancer cells would result
in increased tumor cell radiosensitivity. H460 cells were
treated with either mannitol (5%) or PCI-5002 (0.3–7.5 M)
for 2 hours, then irradiated. After 8 to 10 days, the clonogenic
survival assay showed that the PCI-5002 treatment (7.5 M)
sample had threefold fewer surviving cells (0.03% versus
0.1% surviving fraction, p  0.001) at the 4 Gy dose than the
irradiated control (Figure 1A). Therefore, PCI-5002 treatment
sensitizes H460 lung cancer cells to radiation treatment.
Next, apoptosis was compared in treated and untreated
cells. PCI-5002-treated cells did not show changes in pro-
caspase-3 or cleaved caspase-3 expression (Figure 1B). Nev-
FIGURE 1. PCI-5002 inhibits apoptosis and increases radiosensitivity in H460 non-small cell lung cancer cells. A, Survival is
reduced in irradiated cells treated with PCI-5002. Cells were treated with PCI-5002 (7.5 M) or 5% mannitol for 2 hours,
then irradiated to 2 to 6 Gy (1.8 Gy/min). Cells were washed, then incubated for 8 to 10 days. The surviving fraction was cal-
culated from triplicate samples. p  0.001 (*). B, PCI-5002 does not cleave caspase-3 in treated H460 cells. After treatment
with radiation and/or PCI-5002 (0.3–7.5 M), cells were lysed, and immunoblotting was performed on quantified protein
with antibodies to procaspase, cleaved caspase-3, and actin. C, PCI-5002 treatment decreases cleavage of caspase-3 in irradi-
ated (10 Gy) H460 cells. D, PCI-5002 treatment reduced cytochrome c release in Bak-/- cells. Mitochondria were isolated from
Bax-/- and Bak-/- cells, incubated with PCI-5002 (100–300 nM) and processed with MIB buffer. After the samples were incu-
bated for 3 hours at 37°C, immunoblotting was performed with an antibody to cytochrome c.
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ertheless, with PCI-5002 treatment and radiation (10 Gy),
there was less caspase-3 induction than in the untreated,
irradiated H460 cells (Figure 1C), suggesting that PCI-5002
decreases apoptotic cell death in irradiated cells.
Cytochrome c release is one of the first hallmark steps
of mitochondrial apoptosis. Muldoveanu et al. has previously
shown that Zn2 treatment of bax-/- and bax/bak-/-cells can
inhibit Bid-activated cytochrome c release. This was evalu-
ated with an in vitro assay, which showed increasing Zn2-
dependent homodimerization of Bak, although Bax could
also be inhibited at high Zn2 concentrations.36 When we
assessed Bid-activated cytochrome c release in bax-/- and bak-/-
cells treated with PCI-5002, cytochrome c release in both cell
lines was inhibited at the highest concentration of PCI-5002
(300 nM) but was most uniformly down-regulated when endog-
enous Bak was present (Figure 1D). This data suggest that
PCI-5002 treatment has antiapoptotic effects in part through
inhibitory effects on the proapoptotic Bak protein.
Annexin V staining detects the membrane asymmetry
of apoptotic cells by binding to negatively charged phospho-
lipids in the cell membrane.41 Staining of cells with Annexin
V-FITC and PI followed by flow cytometry allowed the
identification of three cell populations: live cells (Q3: FITC;
PI), early apoptotic cells (Q4: FITC; PI), and late apopto-
tic cells (Q2: FITC; PI) (Figures 2A, B). Although control
and PCI-5002-treated cells had comparable levels of apoptotic
cells (Figure 2B), irradiated samples showed a 2.5-fold and
fivefold reduction of apoptotic cells in the low dose (0.3 M,
p  0.027) and high dose (7.5 M, p  0.0015) of PCI-5002
treatment, respectively. This data suggest that PCI-5002 inhibits
apoptosis in irradiated cells in a dose-dependent manner.
Despite Decreased Apoptosis, PCI-5002-
Treated Cells have Decreased Tumor Cell
Proliferation in an Irradiated Xenograft Mouse
Model
Because of the antiproliferative effect of PCI-5002
treatment in A549 cells, we hypothesized that PCI-5002
treatment of cells in a xenograft mouse model would also
have decreased cell proliferation. For this experiment, 4- to
6-week-old athymic female nude mice were injected into the
left posterior flank with 1  106 H460 cells. Once the tumor
volumes averaged 0.1 cm3, 5% mannitol or PCI-5002 was
injected intraperitoneally for 7 days. In cases where treatment
FIGURE 2. Annexin V staining is
decreased with increased PCI-5002
treatment dose in H460 cells. A,
Cells were analyzed by flow cytom-
etry. Plated H460 cells were treated
with PCI-5002 (0.3 M and 7.5
M) for 2 hours and immediately
irradiated with 10 Gy. After treat-
ment, cells were stained with An-
nexin V FITC and PI for 15 minutes.
Three populations of cells were
identified by cellular gating: live
cells (Q3: FITC; PI), early apo-
ptotic cells (Q4: FITC; PI), and
late apoptotic cells (Q2: FITC;
PI). B, Graphical interpretation of
flow cytometry results. Cells in
quadrants (Q2  Q4) were quanti-
tated, and the percentage of apo-
ptotic cells is shown in each sample.
The percentage of apoptotic cells in
irradiated, PCI-5002 treated cells is
significantly decreased when com-
pared with RT alone. p  0.027 (*);
p  0.0015 (**).
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was combined with radiation, radiation treatment was begun
after the first 2 days of drug treatment alone, at 2 Gy/d for an
additional 5 days. The effect of PCI-5002 treatment on
caspase-3 levels was also tested in this xenograft mouse
model by staining caspase-3 in paraffin-embedded tumor
sections (Figure 3A). Although untreated tumor and PCI-
5002-treated tumor had equivalent levels of caspase-3 stain-
ing, irradiated PCI-5002-treated tumor had 1.8-fold fewer
caspase-3-positive cells than tumors treated with radiation
alone (Figure 3A, p  0.003).
The proliferation index of mice was measured with
Ki67 staining in paraffin-embedded tumors. The control
showed a twofold reduction in the number of Ki67-staining
cells in PCI-5002-treated (100 nmol/kg) tumors than control
tumors, both without (p  0.0001) and with radiation treat-
ment (p  0.0008). This data suggest that the cell prolifera-
tion of tumor cells in a xenograft mouse model is decreased
significantly by PCI-5002 treatment.
PCI-5002 Delays Tumor Growth in an
Irradiated Xenograft Mouse Model
To measure the effects of PCI-5002 treatment on tumor
growth, tumors were measured in each treatment group two
to three times a week. At day 0 (before treatment), all tumors
had an average size of 0.1 cm3. Nevertheless, over the course
of 30 days, tumor growth was significantly delayed in the
irradiated, PCI-5002-treated mice, in comparison with the
other samples (Figures 4A, B). Luciferase activity was sub-
stantially reduced in the PCI-5002-treated, irradiated mice
(Figure 4A), suggesting that combination treatment had the
greatest effect on grafted tumor cells. To reach the threshold
tumor size of 1 cm3, the irradiated, PCI-5002-treated tumors
took 25 days, in comparison with the control (10 days),
PCI-5002-treated (15 days), and irradiated control tumors (22
days) (Figure 4B). This xenograft data suggest that PCI-5002
treatment delays tumor growth in vivo, likely by increasing
the radiosensitive fraction of tumor cells.
Treated mice had stable body weight during the dura-
tion of the experiment (95% of the starting B.W.) (Figure
4C). The largest changes were seen 6 days after the beginning
of the experiment in the combination treatment group but
began to stabilize after this time.
PCI-5002 Radiosensitizes Cells Even in the
Absence of Apoptosis, by Enhancing
Autophagy
We have previously shown that decreased apoptosis is
associated with increased radiosensitivity and autophagy in
lung cancer cells.29 Therefore, we hypothesized that the
effects of PCI-5002 treatment on apoptosis may also confer
radiosensitivity to tumor cells by increasing autophagy. To
test this hypothesis, bax/bak-/- MEF cells were used to pro-
vide an experimental context of reduced apoptotic cell death.
First, we confirmed that bax/bak-/- MEF cells have undetect-
able caspase-3 (Figure 5A). In comparison, WT MEFs also
showed reduced caspase-3 expression with combined PCI-
5002 treatment and radiation treatment (Figure 5A). In the
clonogenic survival assay, PCI-5002-treated MEFs had fewer
surviving cells than the WT control (6 Gy dose: p  0.003),
confirming that the radiosensitivity of PCI-5002-treated cells
was a consistent finding across multiple cell types (Figure
5B). Interestingly, the treatment of bax/bak-/- cells with PCI-
5002 had no apparent effect on radiosensitivity, although
these cells were more radiosensitive than WT MEFs at
baseline (Figure 5B).
FIGURE 3. Despite decreased apo-
ptosis, PCI-5002-treated cells have
decreased tumor cell proliferation.
A, Caspase-3 staining is reduced in
irradiated cells treated with PCI-
5002 (100 nmol/kg). Xenograft
mice were implanted with H460
cells then treated with PCI-5002 for
7 days. Tumors were fixed with par-
affin and stained with caspase-3.
The number of stained cells was
quantified in triplicate samples to
calculate the mean. p  0.003 (*).
B, The cell proliferation index of
PCI-treated cells is decreased in
vivo. As described in (A), tumors
were isolated from xenograft mice
that were treated with PCI-5002.
Paraffin-fixed tumors were then
stained with Ki67 stain, and stained
cells were quantified in triplicate
samples. p  0.0008 (**), p 
0.0001 (***).
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To determine whether PCI-5002-treated cells had
higher levels of autophagy, GFP-LC3 was transfected into
H460 (Figure 5C) and WT MEF (Figure 5D) cells. At 24
hours posttransfection, selected samples were irradiated with
a 5 Gy dose. Punctate LC3 is characteristic for autophagy in
cells because it signifies the lysosomal compartmentalization
of LC3 protein. Punctate LC3 expression was quantified in
cells at 48 hours posttransfection. Autophagy was greater in
irradiated cells than control cells, a finding that we have
previously described.42 In H460 cells, the level of autophagy
in PCI-5002-treated cells without radiation treatment approx-
imated those seen in irradiated H460 cells, suggesting that
PCI-5002 is an active inducer of autophagy (Figure 5C).
Furthermore, PCI-5002 treatment combined with radiation
FIGURE 4. PCI-5002 delays tumor growth in an irradiated xenograft mouse model. A, Tumor growth is decreased in irradi-
ated xenograft mice treated with PCI-5002. After the implantation of 1  106 H460 cells into the flanks of nude athymic
nude mice, tumors were grown for 6 to 8 days before initiating PCI-5002 treatment (100 nmol/kg; 5 days) (day 0). For irradi-
ated and drug-treated samples, mice were treated with PCI-5002 for 2 days before starting irradiation (2 Gy). Radiation treat-
ment was performed for 5 days an hour after drug treatment. Tumors were photographed and scanned on day 10 after injec-
tion with H-460-luc2. B, The tumors in PCI-5002-treated mice are smaller than untreated mice. The tumor volume was
monitored by measuring tumors in three dimensions, 2 to 3 times/wk. The mean tumor volume is shown for each sample
(n  5 mice) over 27 days. C, The body weight (B.W. ratio  B.W. on indicated day posttreatment/baseline B.W.) in PCI-
5002, RT, and combination treatment mice as an indicator of treatment toxicity.
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treatment in H460 cells led to autophagy 40-fold greater than
that seen in control H460 cells (p  0.0001). Similar effects
of PCI-5002 treatment were seen in MEF cells, with com-
bined PCI-5002 and radiation treatment leading to 25-fold
higher autophagy than that in WT MEFs (p  0.0006)
(Figure 5D). As described previously,12 an increased level of
autophagy (18-fold) was noted in bax/bak-/- cells that had
been irradiated (in comparison with bax/bak-/- cells without
radiation, p 0.0002). Therefore, the activation of autophagy
in irradiated cells treated with PCI-5002 approximates that
seen in irradiated cells with reduced apoptosis (Figure 5D).
DISCUSSION
In this study, we hypothesized that the zinc ionophore
PCI-5002 acted as a radiosensitizing agent in non-small lung
cancer cells by enhancing autophagy and decreasing apopto-
sis. To address this question, we used both in vitro MEF and
lung cancer cell culture models and an in vivo xenograft
model to assess the effects of PCI-5002 treatment on tumor
growth.
First, PCI-5002 treatment resulted in increased radio-
sensitivity of H460 cells. In addition, irradiated PCI-5002-
treated cells also had decreased apoptosis, as assayed by
caspase-3 expression, cytochrome c release, and Annexin-V
staining.
Second, to characterize the in vivo effects of PCI-5002
treatment, the implantation of PCI-5002-treated cells resulted
in decreased tumor volumes and proliferation indices than
implanted mannitol-treated cells in an irradiated xenograft
mouse model. Although treatment with PCI-5002 alone did
not effectively reduce tumor size, the combination of PCI-
5002 and RT delayed tumor growth more than RT alone,
which our data show is likely facilitated by decreased apo-
ptosis and increased autophagy. Therefore, PCI-5002 sensi-
FIGURE 5. PCI-5002 radiosensitizes cells even in the absence of apoptosis, by enhancing autophagy. A, PCI-5002 treatment
does not alter levels of caspase-3 cleavage in DKO (Bax/Bak-/-) mouse embryonic fibroblast (MEF) cells. Wild-type (WT) MEF
and Bax/Bak-/- cells were treated with PCI-5002 (100–300 nM) or 5% mannitol for 2 hours, then irradiated with 2 to 6 Gy
(1.8 Gy/min). Immunoblotting of lysed cells was performed 48 hours later with antibodies to procaspase-3, caspase-3, and
actin. B, PCI-5002 treatment does not increase the radiosensitivity of Bax/Bak-/- cells. Cells were treated with PCI-5002 (300
nM) or 5% mannitol for 2 hours, then irradiated to 2 to 6 Gy (1.8 Gy/min). Cells were washed then incubated for 8 to 10
days, before the survival fraction was calculated. p  0.003 (*), p  0.0001 (***). Autophagy is increased in PCI-5002-treated
H460 (C) and MEF cells (D). Cells were transfected with GFP-LC3 plasmid; 24 hours after transfection, irradiated samples re-
ceived 5 Gy. PCI-5002-treated samples received either the 7.5 M (C) or 300 nM (D) dose; 48 hours later, punctate GFP ex-
pression was detected with confocal microscopy. p  0.0006 (**).
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tizes cells to radiation treatment and results in a functional
deficit of tumor cells to proliferate in vivo.
Third, to test the effects of PCI-5002, we treated bax/bak-/-
MEF cells, which have decreased apoptosis.43 Although bax/
bak-/- cells are at baseline more radiosensitive than WT cells,
treatment with PCI-5002 did not result in increased efficiency of
radiation treatment. This data suggest that Bax/Bak is required
for the effects of PCI-5002 on the radiosensitization of tumor
cells. In addition, it corroborates our previous data with
caspase3/7-/-, which suggest that reducing apoptotic cell death
leads to increased radiosensitivity in cells.29
Fourth, we found that increased radiosensitivity correlated
with increased autophagy in irradiated cells. These findings were
demonstrated in both MEFs and H460 cells. Interestingly, the
up-regulation of autophagy in PCI-5002-treated cells approxi-
mated the enhanced autophagy in irradiated bax/bak-/- cells.
These data are consistent with our previous work, which dem-
onstrated that treatment of lung cancer cells with a caspase
inhibitor resulted in increased autophagy.29 We have previously
shown that bax/bak-/- MEF cells have increased Beclin-1 protein
after RT.12 Therefore, it is possible that PCI-5002 treatment does
not synergize with RT to reduce the surviving fraction in the
bax/bak-/- MEF cells clonogenic assay (Figure 5B) because
autophagy is already stimulated in these cells.
Zinc can inhibit apoptotic cell signaling through the
inhibition of caspase or the proapoptotic gene Bak.35,36 A
prior study has demonstrated that zinc inhibited Bak-medi-
ated mitochondrial outer-membrane permeabilization by en-
hancing low-affinity zinc-dependent cBak homodimeriza-
tion.36 The homodimerization of cBak in solution resulted in
decreased cBid-dependent release of cytochrome c. Introduc-
tion of a H164A mutation in the zinc-binding site of the
C-terminal bundle resulted in resistance to the inhibitory
effects of zinc on cytochrome c release.36 These data showed
that zinc-mediated homodimerization is an important regula-
tor of Bak-mediated apoptosis, in addition to the self-regula-
tion imposed by the N-terminus and the conformational
changes of the BH3 peptide-binding central pocket facilitated
by the 3 helix. We have previously shown that in bax/bak-/-
MEF cells, decreased apoptosis is accompanied by increased
radiosensitivity and autophagy.12 Similar results were ob-
served in human breast and lung cancer cells that were treated
with siRNAs targeted to Bax/Bak.12 Interestingly, we show in
this study that PCI-5002 treatment inhibited cytochrome c
release most strongly when endogenous Bak was present,
corroborating the conclusions of the Muldoveanu et al.,36
study detailing the interaction between zinc and Bak. There-
fore, these data suggest that zinc inhibits Bak-mediated (and
to some extent, Bax-mediated) apoptosis and sensitizes cells
to radiation treatment.
We have previously shown that the treatment of H460
NSCLC cells with M867, a reversible chemical caspase-3
inhibitor, resulted in increased autophagy and radiosensitivity
in treated cells. In this study, PCI-5002 treatment not only
resulted in the increased radiosensitivity of H460 and MEF
cells but also of autophagy. Moreover, PCI-5002 treatment
increased autophagy in irradiated WT cells to a similar level
of irradiated bax/bak-/- cells. Therefore, we conclude that
PCI-5002 is a radiosensitizing agent that increases autophagy
in irradiated cells.
Radiation treatment likely increases autophagy in cells
through the induction of an endoplasmic reticulum-mediated
stress response, possibly due to the buildup of misfolded
proteins.44,45 We have previously shown that inhibition of
FIGURE 6. PCI-5002 sensitizes cells
to radiation therapy by inhibiting
apoptosis and increasing autophagic
cell death. PCI-5002 is a zinc iono-
phore that results in increased intra-
cellular Zn2 in treated cells. Apo-
ptosis and autophagy pathway
components are boxed in green
and blue, respectively. Biochemical
analyses revealed that PCI-5002 and
Zn release likely inhibit apoptosis in
part through Bak (boxed in tur-
quoise) regulation. Crosstalk has
been demonstrated between the
autophagy and apoptosis pathways
when oxidative stress or caspase
defects are present. Our data dem-
onstrate that PCI-5002 treatment
results in the increased radiosensitiv-
ity of treated lung cancer cells in
vitro, as well as implanted cells in
an in vivo mouse xenograft tumor
model.
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mTOR with Everolimus/RAD001 radiosensitizes prostate
(PC-3 and DU145), breast, and lung cancer cell lines, a
finding that was associated with induced autophagy and was
enhanced by the biochemical inhibition of apoptosis.12,28,30
Increased autophagy was also been described in malignant
glioma cells.31,46–48 Interestingly, zinc has been shown to
increase autophagy in breast cancer cells treated with Tamox-
ifen, likely because of increased ROS.38,39
Our data support a model in which PCI-5002 radiosen-
sitizes cells by inhibiting apoptosis, which results in in-
creased autophagic cell death. Prior studies show that de-
creased apoptosis with caspase inhibitor treatment resulted in
increased autophagy and nonapoptotic cell death in L929
mammalian cells, a process that was mediated by RIP and
JNK signaling. Increased autophagy and cell death could be
reversed by RNAi treatment that reduced ATG7 or Beclin-1
expression.20 This suggests that caspases may physiologically
inhibit autophagic cell death but that caspase defects in viral
infection (which results in the expression of caspase inhibi-
tors) or in the context of cancer progression unmask the
ability of a cell to undergo autophagic cell death. The level of
autophagic cell death would likely be enhanced further with
the addition of metabolic stress (i.e., radiation treatment-
induced ROS). Therefore, our results suggest that decreased
apoptosis due to PCI-5002 treatment (increased zinc activity)
results in the up-regulation of autophagic cell death in the
face of oxidative stress presented by radiotherapy. Neverthe-
less, other alternative mechanisms accounting for the radio-
sensitization of irradiated cells as a result of PCI-5002 treat-
ment include the direct activation of autophagy by PCI-5002
treatment. Autophagy is increased in PCI-5002-treated cells
that do not undergo radiation, a consequence that could be
due to the effects of increased zinc on apoptosis or on
autophagy directly. The latter mechanism, however, is un-
likely to be a main contributor, as PCI-5002 could not
increase autophagy in bax/bak-/- MEFs, suggesting that zinc
exerts its effects on autophagy through the regulation of
apoptosis. Nevertheless, a direct effect of PCI-5002 on au-
tophagy components cannot be excluded. Next, it is possible
that inhibiting apoptosis leads to increased cell death with
radiation treatment because of a greater accumulation of ROS
from damaged mitochondria or other organelles. In this case,
the up-regulation of autophagy might merely represent an
attempt by the treated cell population to cope with greater
levels of metabolic stress and serve as a prosurvival mecha-
nism. Nevertheless, this hypothesis would not account for the
association between increased autophagy and increased radi-
osensitivity in PCI-5002-treated cells.
In this study, we demonstrate for the first time that the
zinc ionophore PCI-5002 radiosensitizes H460 non-small
lung cancer cells by enhancing autophagy in the context of
reduced apoptosis. Because of the effects of PCI-5002 on
apoptosis and autophagy, we propose that it is a biological
radiosensitizing agent.
These data suggest that PCI-5002 is a promising can-
didate for radiosensitizing lung cancer cells to chemoradia-
tion treatment and provides explanation for why proapoptotic
agents have not demonstrated significant efficacy in clinical
trials.7,8 The effects of PCI-5002 on normal cells remains to
be evaluated; however, the effects of PCI-5002 in the in vivo
xenograft model are promising. Interestingly, although zinc
can have toxic effects on the neurologic, gastrointestinal, and
respiratory systems, zinc supplementation has been shown to
reduce mucositis and dermatitis in patients receiving radio-
therapy for head and neck cancers, allowing more patients to
complete radiation treatment. In addition, a double-blinded
randomized study found that zinc supplementation in-
creased the 3-year local-free survival in patients with advanced
(stages III–IV) head and neck cancer receiving radiation
treatment, although that study emphasized the effects of zinc
on immunity as the likely mechanism.49,50 Nevertheless, this
data suggest that PCI-5002 treatment might have a therapeu-
tic effect on cancer types in addition to lung cancer. Although
PCI-5002 requires additional testing, particularly in clinical
trials, the addition of a radiosensitizing agent to the lung
cancer treatment regimen would potentiate the eradication of
tumor cells. Taken together with our prior reports, we believe
that these data support the simultaneous induction of au-
tophagy and the inhibition of apoptosis as an effective ther-
apeutic approach for the prevention of locally recurrent lung
cancer.
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